Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Hematol Oncol
; 39(3): 336-348, 2021 Aug.
Article
in En
| MEDLINE
| ID: mdl-33583077
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Lymphoma, B-Cell
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Hematol Oncol
Year:
2021
Document type:
Article
Affiliation country:
Grecia
Country of publication:
Reino Unido